Life Sciences

Gene Therapy: The Future is Here
After decades of R&D, numerous lessons learned, and limited initial adoption, gene therapy has finally become a clinically and financially viable option for certain indications globally. In the early 2000’s, gene therapy was
A Blueprint for Biosimilars?
As expected, biosimilars news made top headlines right out of the starting gate in 2015, with Novartis’s biosimilars version of filgrastim gaining a 14-0 positive vote by the FDA’s independent Oncologic Drugs Advisory Committee on